Found: 9
Select item for more details and to access through your institution.
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 2, p. 299, doi. 10.1007/s10549-015-3613-y
- By:
- Publication type:
- Article
Watch Where You Sit!
- Published in:
- Oncology (08909091), 2017, v. 31, n. 12, p. 918
- By:
- Publication type:
- Article
Best of the Blogs.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 9, p. C3
- By:
- Publication type:
- Article
Survivorship Is Not a Passive Sport.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 6, p. 533
- By:
- Publication type:
- Article
Best of the Blogs.
- Published in:
- Oncology (08909091), 2014, v. 28, n. 6, p. 532
- By:
- Publication type:
- Article
STRAIGHTFORWARD ONCOLOGY.
- Published in:
- Oncology (08909091), 2013, v. 27, n. 10, p. 1047
- By:
- Publication type:
- Article
STRAIGHTFORWARD ONCOLOGY.
- Published in:
- Oncology (08909091), 2013, v. 27, n. 9, p. 922
- By:
- Publication type:
- Article
STRAIGHTFORWARD ONCOLOGY.
- Published in:
- Oncology (08909091), 2013, v. 27, n. 8, p. 769
- By:
- Publication type:
- Article
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.
- Published in:
- Clinical Breast Cancer, 2015, v. 15, n. 4, p. 251, doi. 10.1016/j.clbc.2014.09.007
- By:
- Publication type:
- Article